Evidence map›Paper›PMID 40761580›Full record

ArticleThe World Allergy Organization journal2025

Impact of hereditary angioedema attacks on health-related quality of life and work productivity.

Maeve O'Connor, Paula J Busse, Timothy J Craig, Cristine Radojicic, H James Wedner, Sherry Danese, Julie Ulloa, Vibha Desai, Tomas Andriotti, Paul K Audhya and 1 more

Abstract read
In one paragraph

Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Hereditary angioedema and the gastrointestinal tract.The World Allergy Organization journal · 2026
    Article
  2. Article
  3. Article
  4. Impact of injectable HAE on-demand treatments on health-related quality of life: a patient and caregiver interview study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maeve O'ConnorIntegrative Immunology Care, LLC, Charlotte, NC, USA.
Paula J BusseMount Sinai School of Medicine, New York, NY, USA.
Timothy J CraigPenn State University, Hershey, PA, USA.
Cristine RadojicicDuke Health, Durham, NC, USA.
H James WednerWashington University School of Medicine, St. Louis, MO, USA.
Sherry DaneseOutcomes Insights, Inc., Agoura Hills, CA, USA.
Julie UlloaProvidence Internal Medicine, Spokane, WA, USA.
Vibha DesaiKalVista Pharmaceuticals, Inc., Boston, MA, USA.
Tomas AndriottiKalVista Pharmaceuticals, Inc., Boston, MA, USA.
Paul K AudhyaKalVista Pharmaceuticals, Inc., Boston, MA, USA.
Sandra ChristiansenUniversity of California San Diego, La Jolla, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hereditary angioedema (HAE) negatively impacts health-related quality of life (HRQoL). Few studies have characterized impairments to HRQoL, work productivity, and well-being during and following HAE attacks. Methods: Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey. Respondents were categorized into those who did (Treated Cohort) and did not (Untreated Cohort) manage their last attack with on-demand treatment (OD). Adapted versions of the EuroQol-Five Dimensions-Five Levels (EQ-5D-5L), EuroQol Visual Analogue Scale (EQ VAS), and Work Productivity and Activity Impairment-General Health assessments were used. Results: Attacks negatively impacted HRQoL and social and physical aspects of well-being in the Treated (N = 94) and Untreated (N = 20) Cohorts. In the Treated Cohort, mean EQ-5D-5L index score was 0.849 "Today" and 0.568 "During the last treated attack," with the latter score indicating substantial impairment in HRQoL. Mean EQ-5D-5L index scores trended lower as time to OD increased, with mean scores of 0.667 for those treating <1 h and 0.593-0.504 for those treating ≥1 to <8 h from attack onset. The percentage of patients with mild attacks decreased as time to OD increased (from 50% for those treating <1 h to 17-33% for those treating ≥1 h from attack onset), and mean EQ-5D-5L index scores decreased as attack severity increased (mild, 0.742; severe, 0.444). Generally, mean EQ VAS scores decreased as time to OD increased, from 60.1 in those treating <1 h to 53.3 in those treating ≥8 h from attack onset. In the week following attack onset, average levels of absenteeism, presenteeism, and overall work impairment were 15%, 35%, and 39%, respectively. Despite attacks being of milder severity, declines in HRQoL (mean EQ-5D-5L and EQ VAS scores "During the last attack": 0.661 and 73.0, respectively) and impairments in work productivity (mean level of absenteeism, presenteeism, and overall work impairment: 12%, 32%, and 36%, respectively) were also observed in the Untreated Cohort. Conclusions: Late-treated and untreated attacks were associated with reduced HRQoL and work productivity, driven by attack severity. The negative impact of attacks may be reduced by increasing compliance with HAE guidelines (ie, consider OD for all attacks and treat as soon as possible), and by addressing barriers to OD in general and early treatment in particular.

Indexed as

Hereditary angioedemaLong-term prophylaxisOn-demand therapyQuality of lifeWork productivity

Identifiers

PMID40761580
PMCPMC12320545

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.